Study guide
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology
Key Takeaways Explain This Topic AI
Diabetes is diagnosed by HbA1c of 48 mmol/mol or more, fasting glucose of 7.0 mmol/L or more, or a 2-hour OGTT value of 11.1 mmol/L or more, confirmed on a second sample if asymptomatic.
HbA1c is unreliable in haemoglobinopathy, haemolysis, recent transfusion, iron deficiency, pregnancy and chronic kidney disease.
MODY is autosomal dominant, presents before 25 years without ketosis, and HNF1A subtypes are exquisitely sulfonylurea-sensitive.
Last updated: September 2026
Diabetes mellitus represents a heterogeneous group of metabolic disorders characterized by persistent hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. For MRCP(UK) Part 1, candidates must master the diagnostic criteria, non-glycaemic confounders of HbA1c, immunogenetic distinctions between autoimmune and monogenic diabetes, guideline-directed pharmacotherapy under NICE NG28, and surveillance protocols for microvascular end-organ damage.
- 1. Diagnostic Thresholds & Biochemical Confounders
- Diagnostic Criteria (WHO & NICE)
Diabetes mellitus is confirmed when venous plasma glucose or glycated haemoglobin meets validated thresholds:
Fasting Plasma Glucose (FPG): ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L (fasting defined as no caloric intake for at least 8 hours).
2-Hour Post-75g Oral Glucose Tolerance Test (OGTT): ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L .
Random Plasma Glucose: ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L in the presence of classic osmotic symptoms (polyuria, polydipsia, unexplained weight loss, lethargy).
Glycated Haemoglobin (HbA1c): ≥ 48 mmol/mol \ge 48\text{ mmol/mol} ≥ 48 mmol/mol ( 6.5 % 6.5\% 6.5% ). Diagnostic Verification Algorithm:
- Symptomatic Patient (polyuria, polydipsia, weight loss) + 1 abnormal result → Confirmed Diabetes
- Asymptomatic Patient + 1 abnormal result → Requires repeat test on a subsequent day (concordant abnormal result confirms diagnosis)
- Asymptomatic Patient + Discordant results → The test that exceeded the diagnostic threshold should be repeated
Intermediate Hyperglycaemia (Prediabetes)
Impaired Fasting Glucose (IFG): Fasting plasma glucose 6.1 – 6.9 mmol/L 6.1\text{–}6.9\text{ mmol/L} 6.1 – 6.9 mmol/L (WHO) with normal 2-hour OGTT ( < 7.8 mmol/L < 7.8\text{ mmol/L} < 7.8 mmol/L ).
Impaired Glucose Tolerance (IGT): Fasting plasma glucose < 7.0 mmol/L < 7.0\text{ mmol/L} < 7.0 mmol/L and 2-hour OGTT 7.8 – 11.0 mmol/L 7.8\text{–}11.0\text{ mmol/L} 7.8 – 11.0 mmol/L .
Prediabetes HbA1c Range: 42 – 47 mmol/mol 42\text{–}47\text{ mmol/mol} 42 – 47 mmol/mol ( 6.0 – 6.4 % 6.0\text{–}6.4\% 6.0 – 6.4% ).
HbA1c Pitfalls & Non-Glycaemic Confounders
HbA1c reflects average ambient glycaemia over the approximate 120-day lifespan of circulating erythrocytes. Any clinical pathology that alters erythrocyte survival, haemoglobin structure, or glycation kinetics renders HbA1c unreliable:
Mechanism Clinical Conditions Effect on Measured HbA1c Alternative Diagnostic Strategy
Shortened Red Cell Lifespan Haemolytic anaemia, hereditary spherocytosis, splenomegaly, acute blood loss recovery, recent blood transfusion, haemoglobinopathies (HbSS, HbSC, thalassaemia major), erythropoietin therapy, haemodialysis Falsely Low Fasting plasma glucose, 2-hour OGTT, or serum fructosamine (reflects 2–3 weeks of glycaemia)
Prolonged Red Cell Lifespan Iron deficiency anaemia (delayed red cell turnover), vitamin B12 or folate deficiency, asplenia / post-splenectomy, severe hyperbilirubinaemia Falsely High Venous plasma glucose criteria (FPG / OGTT)
Chemical / Assay Interference Uraemia (carbamylated haemoglobin formation), severe chronic alcoholism, high-dose aspirin/vitamin C ingestion, homozygous haemoglobin variants (interfering with ion-exchange HPLC) Falsely Altered (variable direction) Enzymatic / affinity chromatography assays or serial plasma glucose profiles
MRCP Exam Pearl: Diagnostic Situations Where HbA1c Must NOT Be Used:
Suspected Type 1 diabetes (rapid onset).
Pregnancy or gestational diabetes.
Children and young people (<18 years).
Symptoms lasting <2 months.
Acute pancreatic damage or secondary diabetes (e.g., pancreatitis, pancreatectomy, steroid-induced).
Patients on medication causing rapid glucose rise (e.g., systemic high-dose corticosteroids, atypical antipsychotics).
- 2. Pathophysiology, Genetics & Classification
- Type 1 Diabetes Mellitus (T1DM)
Immunopathogenesis: T-cell-mediated autoimmune destruction of insulin-secreting β \beta β -cells within pancreatic islets of Langerhans. Overt clinical presentation occurs once > 80 – 90 % > 80\text{–}90\% > 80 – 90% of β \beta β -cell mass is irreversibly eradicated.
Immunogenetics: Polygenic susceptibility strongly linked to human leukocyte antigen (HLA) class II genes on chromosome 6p21:
High-Risk Alleles: HLA-DR3-DQ2 and HLA-DR4-DQ8 ; individuals who are heterozygous DR3/DR4 carry the highest relative risk (>20-fold).
Protective Allele: HLA-DR2 (specifically DQB1*0602 confers dominant protection).
Circulating Autoantibodies:
Anti-GAD65 (Glutamic Acid Decarboxylase 65): Most sensitive and persistent autoantibody into adult life (~80% positivity at onset).
Anti-IA-2 (Insulinoma-Associated Antigen 2): Marker of rapid β \beta β -cell destruction; common in children.
Anti-ZnT8 (Zinc Transporter 8): Target antigen in secretory granules; detects additional 10–15% of antibody-negative cases.
Anti-Insulin Autoantibodies (IAA): Commonest in young infants; ceases to be diagnostic once exogenous insulin is injected.
C-Peptide Secretion: Cleaved from proinsulin in equimolar amounts to endogenous insulin. In long-standing T1DM, stimulated C-peptide is low or undetectable ( < 200 pmol/L < 200\text{ pmol/L} < 200 pmol/L ). A preserved C-peptide level ( > 600 pmol/L > 600\text{ pmol/L} > 600 pmol/L ) more than 3 years after diagnosis strongly suggests Type 2 or monogenic diabetes.
Type 2 Diabetes Mellitus (T2DM)
Pathophysiology: Characterized by peripheral insulin resistance (skeletal muscle, liver, adipose tissue) combined with progressive pancreatic β \beta β -cell secretory failure. Unchecked hepatic gluconeogenesis causes elevated fasting glucose, while impaired muscle glucose uptake (GLUT4 translocation defect) drives postprandial hyperglycaemia.
Genetics: Highly polygenic (>400 risk loci identified, including TCF7L2 , KCNQ1 , PPARG ), demonstrating higher concordance in monozygotic twins (~70–90%) than Type 1 diabetes (~30–50%).
Monogenic Diabetes: Maturity-Onset Diabetes of the Young (MODY)
MODY accounts for 1–2% of all diabetes cases. It is inherited in an autosomal dominant manner, typically presents before age 25, is non-ketotic, and occurs in the absence of pancreatic islet autoantibodies: MODY Key Subtypes:
- HNF1A-MODY (MODY3, ~70%): Transcription factor defect → Low renal glucose threshold (glycosuria) → Marked hypersensitivity to low-dose sulfonylureas
- GCK-MODY (MODY2, ~30%): Glucokinase sensor defect → Elevated set-point for insulin release → Stable mild fasting hyperglycaemia (5.5–8.0 mmol/L) → No microvascular complications → No pharmacological treatment needed
- HNF4A-MODY (MODY1, ~5%): Transcription factor defect → Neonatal macrosomia, transient neonatal hypoglycaemia → Responsive to sulfonylureas
GCK-MODY in Pregnancy Exception: If the mother has GCK-MODY and the fetus inherits the mutation, the fetus senses maternal glucose as normal; no treatment is needed. If the fetus does not inherit the mutation, maternal hyperglycaemia triggers fetal hyperinsulinaemia and macrosomia; maternal insulin therapy is required.
Latent Autoimmune Diabetes in Adults (LADA)
Often termed "Type 1.5 diabetes". Represents slowly progressive autoimmune destruction in adults aged >30–35 years.
Frequently misdiagnosed as Type 2 diabetes due to adult onset, absence of initial ketoacidosis, and modest response to oral agents.
Diagnostic hallmarks: Anti-GAD65 antibody positivity , absence of metabolic syndrome features, and progression to absolute insulin requirement within months to 5 years.